TP-05 (lotilaner) High Dose
Phase 2
TP-05 (lotilaner) High Dose is one of 9 therapeutic programs targeting Lyme disease. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
14 competitors in Lyme Disease
#DrugCompanyPhaseTrials
1Achromycin V
WWyeth-Lederle Vaccines
Approved
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Antabuse
TevaPhase 2
Antibiotics
MMelinta Therapeutics, Inc.
Phase 3
VLA15
PfizerPhase 3
Psilocybin
COMPASS PathwaysPhase 1
TP-05 (lotilaner) High Dose
TTarsus Pharmaceuticals, Inc.
Phase 2
Ceftriaxone Treatment
NNantes University Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for TP-05 (lotilaner) High Dose. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company
- TTarsus Pharmaceuticals, Inc.